Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H20N6O |
| Molecular Weight | 396.4445 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(=CC=N1)C2=C(C)C=C(CC(=O)NC3=CC=C(C=N3)C4=CN=CC=N4)C=N2
InChI
InChIKey=XXYGTCZJJLTAGH-UHFFFAOYSA-N
InChI=1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)
| Molecular Formula | C23H20N6O |
| Molecular Weight | 396.4445 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26658453
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26658453
Novartis Oncology (previously Novartis) is developing WNT-974 (formerly LGK 974), a first-in-class selective small molecule inhibitor of O-acyltransferase. WNT-974 is under development for the treatment of cancers that are driven by the Wnt pathway in a Wnt ligand-dependent manner. Upon oral administration, WNT-974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers
Originator
Sources: http://adisinsight.springer.com/drugs/800034218
Curator's Comment: # Novartis
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1255163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26522946 |
0.4 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
72.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33941878/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
WNT-974 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
434 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33941878/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
WNT-974 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33941878/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
WNT-974 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33941878/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
WNT-974 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02649530
10 mg of WNT-974 daily by mouth
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26658453
Ascites cells from ovarian cancer patients were treated with 1 uM WNT-974 for 7 days. Flow cytometry demonstrated fewer cells from ascites samples in the G2 phase and more in the G1 and S phases after treatment with WNT-974.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:59:20 GMT 2025
by
admin
on
Mon Mar 31 21:59:20 GMT 2025
|
| Record UNII |
U27F40013Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000175310
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
1243244-14-5
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
DB12561
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
46926973
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
U27F40013Q
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
C116860
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |